最新ニュース Revvity (NYSE:RVTY) 株価情報

Revvity

Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.

Revvity Inc

Catheter Precision, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#NYSE">VTAK</a>), a U.S.-based innovative medical device company focused on electrophysiology products, today announced that it has brought on board Philip Anderson, to take on the position of Chief Financial Officer. Margrit Thomassen, who has been our Interim Chief Financial Officer, will continue with the company in the role of Controller.

News

Management

VTAK

Catheter Precision Announces Philip Anderson As New Chief Financial Officer

Cantor Fitzgerald analyst Ross Osborn initiates coverage on Anteris Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVR#NASDAQ">AVR</a>) with a Overweight rating and announces Price Target of $9.

Price Target

Initiation

Analyst Ratings

Cantor Fitzgerald Initiates Coverage On Anteris Technologies with Overweight Rating, Announces Price Target of $9

WIIM

INVZ

Innoviz shares are trading higher after the company announced it will showcase its perception software at CES 2025 and demonstrate how it runs with the NVIDIA DRIVE AGX Orin platform/

As of Jan. 7, 2025, two stocks in the energy sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the<a href="https://www.benzinga.com/topic/rsi"> RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">PTL Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTLE#NASDAQ">PTLE</a>)</h3>
<ul>
<li>On Nov. 6, PTL Limited announced full exercise of underwriter&#8217;s over-allotment option. The company's stock surged around 33% over the past month and has a <a href="https://www.benzinga.com/quote/PTLE">52-week high of $12.84</a>.</li>
<li>RSI Value: 76.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>PTLE Price Action: Shares of PTL jumped 37.6% to close at $10.17 on Monday.</li>
</ul>
<h3 class="wp-block-heading">Mind Technology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIND#NASDAQ">MIND</a>)</h3>
<ul>
<li>On Dec. 10, Mind Technology announced better-than-expected third-quarter financial results. Rob Capps, MIND&#8217;s President and Chief Executive Officer, stated, &#8220;We are very pleased to report that third quarter revenue grew 21% sequentially and 143% over last year&#8217;s third quarter. We continue to capitalize on macro tailwinds and customer engagement to stimulate order flow and generate improved results. We are also continually working to improve our execution, efficiency and cost structure, which we expect to contribute to sustained profitability in future quarters." The company's stock gained around 73% over the past month and <a href="https://www.benzinga.com/quote/MIND">has a 52-week high </a>of $8.55.</li>
<li>RSI Value: 78.7</li>
<li>MIND Price Action: Shares of Mind Technology fell 5.6% to close at $7.25 on Monday.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42839544/wells-fargo-gears-up-for-q4-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">Wells Fargo Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

MIND

PTLE

Top 2 Energy Stocks That Are Ticking Portfolio Bombs

Chardan Capital analyst Daniil Gataulin maintains Oculis Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCS#NASDAQ">OCS</a>) with a Buy and maintains $28 price target.

Chardan Capital Maintains Buy on Oculis Holding, Maintains $28 Price Target

Partnership further strengthens Holley's position as a global leader in automotive aftermarket performance solutions
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.holley.com%2F&amp;esheet=54174143&amp;newsitemid=20250106200844&amp;lan=en-US&amp;anchor=Holley+Performance+Brands&amp;index=1&amp;md5=2b5b53529b7f2f96fcfdf35360f5c5fe">Holley Performance Brands</a> ("Holley") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLLY#NYSE">HLLY</a>), a leader in automotive aftermarket performance solutions, today announced a perpetual exclusive license agreement with Cataclean Global Limited ("Cataclean") for the North American market. The enhanced partnership allows Holley to develop, manufacture, market, distribute and sell Cataclean branded products in the U.S., Canada and Mexico. The transaction total purchase price is $23.8 million.

Global

HLLY

Holley Performance Brands Announces A Perpetual Exclusive License Agreement With Cataclean Global For The North American Market; The Enhanced Partnership Allows Holley To Develop, Manufacture, Market, Distribute And Sell Cataclean Branded Products In The U.S., Canada And Mexico; The Transaction Total Purchase Price Is $23.8M

Oppenheimer analyst Rupesh Parikh maintains Ulta Beauty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) with a Outperform and raises the price target from $505 to $515.

ULTA

Oppenheimer Maintains Outperform on Ulta Beauty, Raises Price Target to $515

NVDA

UBER

Uber Technologies and Nvidia shares are trading higher after the two companies announced a strategic partnership on AI technology for autonomous cars.

&nbsp;Innoviz Perception Software offers key features running with the NVIDIA&nbsp;DRIVE AGX Orin platform
Innoviz booth at CES is on West Hall, booth #4216
TEL AVIV, Israel, Jan. 7, 2025 /PRNewswire/ -- <a href="https://innoviz.tech/">Innoviz Technologies</a> Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVZ#NASDAQ">INVZ</a>) (the "Company" or "Innoviz"), a leading Tier-1 supplier of high-performance, automotive-grade LiDAR sensors and perception software, is proud to announce its latest technological advancements, which will be showcased at CES 2025. Highlighting the power of its perception software, Innoviz will demonstrate how it runs seamlessly with the NVIDIA DRIVE AGX Orin platform, offering a range of software-driven features designed to accelerate autonomous driving applications.
 &nbsp;

Innoviz, In Collaboration With NVIDIA, Showcases Cutting-Edge Perception Software With NVIDIA DRIVE AGX Orin At CES 2025, Unveiling New Software-Driven Features

Offerings

LFWD

Lifeward Announces $5M Registered Direct Offering Priced At-The-Market; Issues 1.82M Shares At $2.75 Each And Short-Term Warrants With $2.75 Exercise Price

Stephens &amp; Co. analyst Jeff Garro reiterates Privia Health Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRVA#NASDAQ">PRVA</a>) with a Overweight and maintains $26 price target.

Reiteration

PRVA

Stephens & Co. Reiterates Overweight on Privia Health Gr, Maintains $26 Price Target

Development advancing to verification and testing phase; Aims to future-proof design, lower componentry costs and improve manufacturing
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fnanovibronix.com%2F%3Fgad_source%3D1&amp;esheet=54174216&amp;newsitemid=20250107583432&amp;lan=en-US&amp;anchor=NanoVibronix%2C+Inc.&amp;index=1&amp;md5=164cc763a5b5c3a75a625f09d605ac2f">NanoVibronix, Inc.</a>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) (the "Company"), a medical device company that produces the UroShield&#xAE;, PainShield&#xAE; and WoundShield&#xAE; Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced a third-party contractor engaged by the Company has completed the design phase for the development of the Company's next generation PainShield&#xAE; and UroShield&#xAE; devices.
During the design phase, which was completed in December 2024, the third-party contractor developed prototypes of the Company's next generation PainShield&#xAE; and UroShield&#xAE; devices that aim to reduce both the cost of assembly and the risk profile and minimize user burden.

Biotech

General

NAOV

NanoVibronix Announces Completion Of Design Phase For Next-Gen PainShield And UroShield Devices, Advancing To Verification And Testing, Aiming To Lower Costs And Enhance Manufacturing

Oppenheimer analyst Owen Lau maintains TransUnion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRU#NYSE">TRU</a>) with a Outperform and lowers the price target from $115 to $112.

Oppenheimer Maintains Outperform on TransUnion, Lowers Price Target to $112

Macro Notification

Retail Sales

Adobe Analytics Data Shows Consumers Spent $241.4B Online From Nov. 1 To Dec. 31, Up 8.7% YoY; Electronics Up 8.8%, Apparel Up 9.9%, Furniture/Home Goods Up 6.8%

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4334909-1&amp;h=2013505765&amp;u=https%3A%2F%2Fneovolta.com%2F&amp;a=NeoVolta+Inc">NeoVolta Inc</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOV#NASDAQ">NEOV</a>) ("NeoVolta"), a leading innovator in energy storage solutions, is pleased to announce the appointment of Michael Mendik, PhD, MBA, as its new Chief Operating Officer (COO). With a distinguished career spanning over two decades in international business management, strategy, and development, Michael brings a wealth of experience and a proven track record of driving profitability and growth in the renewable energy sector.

NEOV

NeoVolta Appoints Michael Mendik As Chief Operating Officer

A savvy trader has capitulated on the booming AI agent coin vertical, pocketing an eight figure sum by <a href="https://www.benzinga.com/money/how-to-trade-cryptocurrency">identifying trending coins early</a>.
What Happened: Lookonchain <a href="https://x.com/lookonchain/status/1876539012409856366">data</a> highlighted the trader&#8217;s details, who achieved a stunning 89.07%-win rate in the past 30 days. 
His standout trades include purchasing 9.16 million ai16z (CRYPTO: AI16Z) on Oct. 25, 2024, for only 18 Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>), worth $3,000.
Out of the total, he sold 1.32 million tokens for $1.71 million and continues to hold 7.85 million tokens worth $17.26 million. 
This takes his total profit to $19 million, marking a 6,400x return.
He also purchased 17.31 million Fartcoin (CRYPTO: FARTCOIN) tokens for $12,500 when its valuation stood at only $83,000.
He then sold 6.71 million tokens for $5.41 million and continues to hold 10.6 million tokens worth $12.83 million. 
The total profit of $18 million marked a 1,490 return.
The trader&#8217;s speculative plays include recent investments in low-cap tokens such as EEF, DEAL, GG, SXBT, FARTOLOGY, and TBOO. His latest major acquisition was OPAIUM, purchased for 400 SOL, valued at $86,000
Also Read: <a href="https://www.benzinga.com/25/01/42780221/from-giggles-to-gains-fartcoin-hits-new-all-time-high-equals-papa-johns-valuation">Fart Coin Goes From Giggles To Gains As Meme Coin Hit New Highs, Equals Papa John&#8217;s Valuation</a>
Why It Matters: Fartcoin and ai16z have posted impressive 7-day gains of 49% and 22%, respectively.
The trending AI coins have caught the attention of crypto traders and analysts, who speculate how long the run can be sustained. 
Lark Davis, a widely-followed crypto analyst, noted that Fartcoin's returns over the past two months have outperformed the S&amp;P 500's cumulative performance since 1990.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">If you bought FARTCOIN 2 months ago, you have outperformed the S&amp;P500 since 1990. <a href="https://t.co/6QSHDZnfVn">pic.twitter.com/6QSHDZnfVn</a>
&mdash; Lark Davis (@TheCryptoLark) <a href="https://twitter.com/TheCryptoLark/status/1876259991524434389?ref_src=twsrc%5Etfw">January 6, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Doc, a pseudonymous crypto trader, <a href="https://x.com/docXBT/status/1876391867279097932">commented</a> that while Fartcoin's range and trend aren't perfect, the daily holds merit further observation and could indicate further upside.
Ai16z, another AI agent coin, hit milestones, such as a 38% rally propelling its market cap from $1.4 billion to $1.9 billion.
It also plans an open-source Layer-1 blockchain and token launchpad.
According to Cryptocurrency Inside, ai16z now <a href="https://x.com/Crypto_Inside_/status/1876582759151321104">ranks</a> among the top meme coins by trading volume, alongside Dogecoin, Shiba Inu, and Pepe.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42789674/dogecoin-shiba-inu-redefine-meme-coin-phenomenon-that-extends-beyond-mere-speculation-report">Dogecoin, Shiba Inu Redefine Meme Coin Phenomenon That &#8216;Extends Beyond Mere Speculation&#8217;: Report</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$SOL

Forget Dogecoin, Shiba Inu — One Trader Made $37 Million With 2 Booming AI Agent Coins

Key Preparations Underway Including Manufacturing Scale-Up, Provider Engagement, Reimbursement Efforts, And Patient Support Programs

CTOR

CTXR

Citius Pharmaceuticals And Citius Oncology Announce LYMPHIR Commercial Launch Set For First Half Of 2025

D. Boral Capital analyst Jason Kolbert maintains Immunic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMUX#NASDAQ">IMUX</a>) with a Buy and maintains $17 price target.

IMUX

D. Boral Capital Maintains Buy on Immunic, Maintains $17 Price Target

President-elect Donald Trump's nominee for the Securities and Exchange Commission (SEC), Paul Atkins, drew attention for his industry-friendly track record and potential to reshape the agency's enforcement priorities.
What Happened: Atkins, a former SEC commissioner, is known for his skepticism of corporate penalties and support for a lighter regulatory approach. During his tenure from 2002 to 2008, Atkins voted against at least ten enforcement actions, including cases involving IBM and Citigroup. He argued that corporate fines unfairly penalize shareholders already harmed by misconduct.
As per experts, Atkins' dissenting votes during his SEC service suggest his preference for penalizing individuals rather than corporations, reflecting his broader criticism of the agency's enforcement process, Reuters reported on Tuesday. 
Former SEC staff, including Gregory Faragasso, described him as meticulous and demanding, stating, "He put us through our paces and pushed for precision in enforcement matters."
Tyler Gellasch of the Healthy Markets Association remarked, "His nomination should bring down the stress levels and ambient heart rates for compliance staffers."
Why It Matters: If confirmed, Atkins' leadership could lead to a significant departure from the SEC's aggressive enforcement stance under current Democratic Chair Gary Gensler. Gensler's SEC levied <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42323248/trump-nominates-paul-atkins-as-sec-chair-emphasizing-digital-assets-as-key-to-making-america-greater">over $20 billion in penalties</a>, targeting systemic risks and corporate malfeasance. In contrast, Atkins' focus is expected to shift toward addressing clear investor losses, such as scams and frauds, rather than pursuing broader corporate accountability.
This shift could benefit major corporations, including Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), Coinbase Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) and BlackRock, which have faced intense scrutiny in recent years. Critics worry that a reduced focus on corporate penalties could embolden large firms to take risks, potentially exposing markets to systemic dangers. 
Atkins was recently <a href="https://www.benzinga.com/24/12/42495805/trumps-sec-nominee-paul-atkins-under-ethical-scrutiny-over-3-million-consulting-payments">facing ethical scrutiny </a>over his connections to financial entities he may soon regulate. Atkins founded Patomak Global Partners in 2009, a consultancy firm that has earned over $3 million in fees from banks, fintech firms, and cryptocurrency exchanges over the past decade, according to public records analyzed by Barron's.
Price Action: As per <a href="https://pro.benzinga.com">Benzinga Pro</a>, SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) which tracks the S&amp;P 500 had dropped by 1.54% in the past one month while the Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) climbed up by 0.41% in the same time, as of Tuesday pre-market hours.
Read Also: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42813324/trumps-universal-tariff-plans-take-shape-analysts-expect-stronger-for-longer-greenback">Trump&#8217;s Universal Tariff Plans Take Shape, Analysts Expect &#8216;Stronger For Longer&#8217; Greenback</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Wikimedia Commons

COIN

TSLA

Trump's SEC Pick Likely To 'Bring Down The Stress Levels' Of Wall Street With Easier Enforcement Ride

Oppenheimer analyst Brian Bittner maintains Sweetgreen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SG#NYSE">SG</a>) with a Outperform and lowers the price target from $45 to $41.

Oppenheimer Maintains Outperform on Sweetgreen, Lowers Price Target to $41

Stifel Nicolaus analyst Daniel Arias maintained a Hold rating on Revvity (RVTY – Research Report) on November 25 and set a price target of $120.00....

Stifel Nicolaus Remains a Hold on Revvity (RVTY)

Janus Henderson Enterprise Fund Q3 2024 Commentary

Janus Henderson Mid Cap Growth Managed Account Q3 2024 Commentary

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AnaptysBio (ANAB – Research Report), Revvity (RVTY –...

Analysts Offer Insights on Healthcare Companies: AnaptysBio (ANAB), Revvity (RVTY) and McKesson (MCK)

BofA upgraded Revvity (RVTY) to Buy from Neutral with a $138 price target Having transformed its business over the last few years, the firm sees th...

Revvity upgraded to Buy from Neutral at BofA

Safe Biopharma: Revvity's Recurring Revenues And Diagnostics

Citi analyst Patrick B Donnelly maintained a Buy rating on Revvity (RVTY – Research Report) today and set a price target of $145.00. Patrick B Donn...

Revvity's Strategic Market Position and Anticipated Growth Drive Buy Rating

UBS says 'underweight the names with high China exposure'

Evercore ISI lowered the firm's price target on Revvity (RVTY) to $125 from $134 and keeps an Outperform rating on the shares. In the firm's 2025 o...

Revvity price target lowered to $125 from $134 at Evercore ISI

In a report released yesterday, Eve Burstein from Bernstein maintained a Buy rating on Revvity (RVTY – Research Report), with a price target of $14...

Bernstein Remains a Buy on Revvity (RVTY)

AAPL

ANAB

CNSWF

DLTR

EBAY

FLEX

FWONA

FWONB

FWONK

GDDY

ICUI

IFCZF

JAAA

JBBB

JMBS

JSMD

JSML

LPLA

LRCX

LULU

NXPI

OTIS

RKLIF

RVTY

SCHW

SSNC

VNLA

VTRS

Press Releases

Revvity To Hold Earnings Call on Monday, November 4, 2024

Revvity Highlights its Strong Progress on Sustainability and Workplace Culture in 2024 Impact Report

Revvity Introduces Transcribe AI: Revolutionizing Data Entry in Clinical Laboratories

Revvity Board Declares Quarterly Dividend

Revvity Announces Financial Results for the Third Quarter of 2024

Revvity to Host Investor Day and Updates Organizational Structure to Reflect Recent Transformation

Revvity to Present at 7th Annual Evercore ISI HealthCONx Conference

Scale Biosciences and Revvity's BioLegend Launch First-of-its-Kind Solution for High Parameter Protein Profiling of Single Cells

Revvity Broadens Relationship with Genomics England to Advance Genomics in the UK

Revvity to Present at J.P. Morgan Healthcare Conference

Agilent Technologies

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solns

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Revvity

ニュース

最新ニュース Revvity (NYSE:RVTY) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル